Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.

Sathyanarayana BK, Hahn Y, Patankar MS, Pastan I, Lee B.

BMC Struct Biol. 2009 Jan 7;9:1. doi: 10.1186/1472-6807-9-1.

2.
3.

Otoancorin, an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22.

Zwaenepoel I, Mustapha M, Leibovici M, Verpy E, Goodyear R, Liu XZ, Nouaille S, Nance WE, Kanaan M, Avraham KB, Tekaia F, Loiselet J, Lathrop M, Richardson G, Petit C.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6240-5. Epub 2002 Apr 23.

4.

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellström I.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6.

5.

Mesothelin: a new target for immunotherapy.

Hassan R, Bera T, Pastan I.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. Review.

6.

Exon deletion in the MSLN gene encoding MPF/mesothelin precursor protein during Laurasiatherian mammal evolution.

Kim DS, Hahn Y.

Int J Mol Med. 2011 Feb;27(2):289-93. doi: 10.3892/ijmm.2010.573. Epub 2010 Dec 2.

PMID:
21132261
7.

Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.

Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S, Hino O.

Oncol Rep. 2008 Dec;20(6):1375-80.

PMID:
19020717
8.

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.

Mol Cancer. 2006 Oct 26;5(1):50.

9.

A binding domain on mesothelin for CA125/MUC16.

Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M.

J Biol Chem. 2009 Feb 6;284(6):3739-49. doi: 10.1074/jbc.M806776200. Epub 2008 Dec 15.

10.

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A.

J Biol Chem. 2004 Mar 5;279(10):9190-8. Epub 2003 Dec 15.

11.

Clinical impacts of mesothelin expression in gastrointestinal carcinomas.

Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F, Mizukami T, Konishi Y, Tahara M, Kamiyama T, Hino O, Taketomi A, Todo S.

World J Gastrointest Pathophysiol. 2016 May 15;7(2):218-22. doi: 10.4291/wjgp.v7.i2.218. Review.

12.

Characterization, molecular cloning and expression of megakaryocyte potentiating factor.

Yamaguchi N, Yamamura Y, Konishi E, Ueda K, Kojima T, Hattori K, Oheda M, Imai N, Taniguchi Y, Tamura M, Ochi N.

Stem Cells. 1996;14 Suppl 1:62-74.

13.

Mesothelin variant 1 is released from tumor cells as a diagnostic marker.

Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20.

14.

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.

Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31.

15.

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.

J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.

16.

Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.

Dis Markers. 2013;35(2):119-27. doi: 10.1155/2013/874212. Epub 2013 Aug 6.

17.

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.

Ma J, Tang WK, Esser L, Pastan I, Xia D.

J Biol Chem. 2012 Sep 28;287(40):33123-31. Epub 2012 Jul 11.

18.

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.

PMID:
20075387
19.
20.

Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.

Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, Yamaue H.

Cancer Sci. 2012 Apr;103(4):739-46. doi: 10.1111/j.1349-7006.2012.02214.x. Epub 2012 Feb 23.

Supplemental Content

Support Center